Prostatectomy News and Research RSS Feed - Prostatectomy News and Research

MRI-guided focal laser ablation could be feasible, safe in prostate cancer patients

MRI-guided focal laser ablation could be feasible, safe in prostate cancer patients

Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation - the precise application of heat via laser to a tumor - is both feasible and safe in men with intermediate risk prostate cancer. [More]
Robotic-assisted radical prostatectomy may reduce risk of blood loss, prolonged hospital stays in obese men

Robotic-assisted radical prostatectomy may reduce risk of blood loss, prolonged hospital stays in obese men

In obese prostate cancer patients, robotic-assisted surgery to remove the prostate reduces the risk of blood loss and prolonged hospital stays, a Loyola Medicine study has found. [More]
Patient-physician communication helps improve quality of life for prostate cancer survivors

Patient-physician communication helps improve quality of life for prostate cancer survivors

For prostate cancer patients who had their prostates surgically removed, patient-physician communication was key for helping them cope with their disease and for improving their health-related quality of life. [More]
SBRT for prostate cancer treatment offers higher cure rate than many traditional approaches

SBRT for prostate cancer treatment offers higher cure rate than many traditional approaches

A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center. [More]
Salvage radical prostatectomy can improve outcomes in prostate cancer patients

Salvage radical prostatectomy can improve outcomes in prostate cancer patients

Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy. [More]
New study finds link between vitamin D deficiency and aggressive prostate cancer

New study finds link between vitamin D deficiency and aggressive prostate cancer

A new study provides a major link between low levels of vitamin D and aggressive prostate cancer. Northwestern Medicine research showed deficient vitamin D blood levels in men can predict aggressive prostate cancer identified at the time of surgery. [More]
Light reflectance spectroscopy may lead to real-time tissue analysis during prostate cancer surgery

Light reflectance spectroscopy may lead to real-time tissue analysis during prostate cancer surgery

Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85 percent accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery. [More]
Active surveillance recommended for low-risk prostate cancer

Active surveillance recommended for low-risk prostate cancer

For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society of Clinical Oncology. [More]
ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

Advances in Radiation Oncology, ASTRO's new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy. [More]
Study looks at post-treatment resources for prostate cancer patients transitioning to survivorship

Study looks at post-treatment resources for prostate cancer patients transitioning to survivorship

The System Partner of Rutgers Cancer Institute of New Jersey, Meridian Health is joining forces with Rutgers Cancer Institute in offering access to a research study aimed at prostate cancer patients who are transitioning to survivorship. [More]
New prognostic biomarker may help determine risk of prostate cancer-related death

New prognostic biomarker may help determine risk of prostate cancer-related death

Researchers at the University of Copenhagen have identified a new prognostic biomarker: the neuropeptide pro-NPY, which may help determine the risk of dying from prostate cancer. This particular type of protein is very specific to prostate cancer cells and could help identify whether newly diagnosed patients require radical prostatectomy surgery or if it is safe to delay surgery. [More]
High intensity focused ultrasound provides important treatment for men with prostate cancer

High intensity focused ultrasound provides important treatment for men with prostate cancer

For the estimated 220,000 men who will be diagnosed with prostate cancer this year, deciding on a method of treatment can be a challenge. Some with early-stage cancer pursue a "wait and watch" option, also called active surveillance, while others with more severe cancer immediately pursue surgery, including prostatectomy (removal of the prostate). [More]
New imaging test detects prostate cancer much better than any other tests in use today

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today. [More]
African American men with prostate cancer have significantly lower PSA density than Caucasian men

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs. [More]

Study: Prostate surgery patients have unrealistic expectations regarding postoperative sexual function

Patients who have undergone radical prostatectomy often have largely unrealistic expectations with regard to their postoperative sexual function, new research shows. [More]
UCLA study finds cost variation across entire care process for low-risk prostate cancer

UCLA study finds cost variation across entire care process for low-risk prostate cancer

Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer - from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing. And they found a wide variation in costs for the various available treatments that remained consistent over a 12-year period, indicating a better method to monitor costs could save valuable healthcare dollars, said study first author Dr. Aaron Laviana, a fifth year urology resident. [More]
Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital. [More]
Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality. [More]
Robotic surgeon offers free consultation for patients diagnosed with prostate cancer

Robotic surgeon offers free consultation for patients diagnosed with prostate cancer

September marks the beginning of Prostate Cancer Awareness Month. World renowned robotic prostate cancer surgeon, Dr. David Samadi, is offering a free phone consultation for patients newly diagnosed with Prostate Cancer. [More]
PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy. [More]
Advertisement